Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hARD Regimen for T-cell Lymphoma
NCT04639843Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Nov 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of duvelisib in T-cell lymphoma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Safety and tolerability and Maximum Tolerated Dose at 21 days. Planned start Nov 2022; status: withdrawn.
02
Drugs
duvelisib
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT04639843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04639843.